Literature DB >> 12591189

Management of hepatitis C.

Alfredo Alberti1, Luisa Benvegnù.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12591189     DOI： 10.1016/s0168-8278(03)00008-4

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  23 in total

1.  Understanding the natural history of chronic HBV and HCV infections.

Authors:  David L Thomas; Adrian M Di Bisceglie; Harvey J Alter; Norah A Terrault
Journal:  J Fam Pract       Date:  2010-04       Impact factor: 0.493

2.  A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy.

Authors:  Eugene Lin; Yuchi Hwang
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

3.  Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis?

Authors:  Rosilene G Badiani; Vitória Becker; Renata M Perez; Carla A L Matos; Lara B Lemos; Valéria P Lanzoni; Luis Eduardo C Andrade; Alessandra Dellavance; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

4.  Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.

Authors:  Hidetsugu Saito; Shinichiro Tada; Hirotoshi Ebinuma; Hiromasa Ishii; Kazuo Kashiwazaki; Masahiko Takahashi; Nobuhiro Tsukada; Jiro Nishida; Shin Tanaka; Hiroshi Shiozaki; Toshifumi Hibi
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

5.  Broad differences between the COBAS ampliprep total nucleic acid isolation-COBAS TaqMan 48 hepatitis C virus (HCV) and COBAS HCV monitor v2.0 assays for quantification of serum HCV RNA of non-1 genotypes.

Authors:  Philippe Colson; Anne Motte; Catherine Tamalet
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

6.  Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.

Authors:  Eiichi Ogawa; Norihiro Furusyo; Kazuhiro Toyoda; Hiroaki Taniai; Shigeru Otaguro; Mosaburo Kainuma; Masayuki Murata; Yasunori Sawayama; Jun Hayashi
Journal:  BMC Gastroenterol       Date:  2010-04-16       Impact factor: 3.067

Review 7.  Treatment of hepatitis C virus infection.

Authors:  Kilian Weigand; Wolfgang Stremmel; Jens Encke
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

8.  Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.

Authors:  Gaetano Scotto; Vincenzina Fazio; Chiara Fornabaio; Alessandra Tartaglia; Rocco Di Tullio; Annalisa Saracino; Gioacchino Angarano
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 9.  Safety of interferon beta treatment for chronic HCV hepatitis.

Authors:  D Festi; L Sandri; G Mazzella; E Roda; T Sacco; T Staniscia; S Capodicasa; A Vestito; A Colecchia
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

10.  L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.

Authors:  Marcello Romano; Marco Vacante; Erika Cristaldi; Valentina Colonna; Maria Pia Gargante; Lisa Cammalleri; Mariano Malaguarnera
Journal:  Dig Dis Sci       Date:  2007-10-16       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.